ReviewCurrent cardiology reports2025
Lipid-Lowering Therapies and Cognition in Older Adults: A Narrative Review and Clinical Considerations.
Review in Current cardiology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Statin use and cognitive outcomes in older adults.American journal of preventive cardiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purpose of reviewThis review will evaluate current data on broadly used lipid lowering agents in relation to cognition in older adults and highlight key findings and research gaps to guide clinical practice and future guidelines. RECENT
findingsEvidence from observational studies and randomized controlled trials indicate no significant association between statin use and cognitive decline, with some data suggesting potential protective effects. While there is insufficient data on inclisaran’s effect on cognition, monoclonal antibodies PCSK9 inhibitors, ezetimibe and bempedoic acid appear neurocognitively safe. Current literature does not conclusively elucidate the association between lipid-lowering therapies and cognitive outcomes in older adults, though existing data, particularly for statins, largely suggest neutral or potentially protective effects. Clinicians should continue prescribing LLT to eligible patients, and future research should prioritize long-term studies that incorporate cognitive outcomes in a diverse group of older adults to guide individualized care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.